ethisterone and Adenocarcinoma

Various changes that have been observed after intrauterine exposure to exogenous hormones are presented. Often, alterations observed after exogenous maternal hormone therapy consist of varying degrees of masculinization of the female genitalia. The following specific drug interactions are described in some detail: 1) effects of progestational agents and androgens on female genitalia; 2) relationship of corticosteroids to the development of cleft palate; and 3) effects of synthetic estrogens (e.g., diethylstilbestrol) on the female reproductive tract. The discussion closes with a review of the association of therapy with such drugs to the delayed appearance of clear-cell adenocarcinoma of the genital tract in young women.

Topics: Abnormalities, Drug-Induced; Adenocarcinoma; Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Bone and Bones; Cleft Palate; Diethylstilbestrol; Disorders of Sex Development; Estrogens, Conjugated (USP); Ethinyl Estradiol; Ethisterone; Female; Fetus; Genital Neoplasms, Female; Gestational Age; Hormones; Humans; Infant, Newborn; Medroxyprogesterone; Mestranol; Methandrostenolone; Methyltestosterone; Norethindrone; Pregnancy; Pregnancy Complications; Progesterone; Testosterone

A series of new D-ring ethisterones substituted with 1,4-1,2,3-triazoles were obtained in a facile manner via click chemistry reactions. The new compounds were characterized by multinuclear NMR spectroscopy, mass spectrometry, IR and unequivocally by single crystal X-ray diffraction studies for compound 1. The cytotoxic activity of these derivatives was tested against a series of human cancer cell lines including human glioblastoma (U-251), human prostatic adenocarcinoma (PC-3), human colorectal adenocarcinoma (HCT-15), human mammary adenocarcinoma (MCF-7), human chronic myelogenous leukemia (K562), and human lung adenocarcinoma (SKLU-1). Derivatives (3, X=Cl) and (5, X=I) showed promising cytotoxicity activities for leukemia adenocarcinoma (K562) and lung adenocarcinoma (SKLU). CI

Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Drug Screening Assays, Antitumor; Ethisterone; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Triazoles

A case of endometrial adenocarcinoma in a patient with Turner's syndrome who had received long term combined oestrogen-progestogen therapy is described.. This is a case report of endometrial adenocarcinoma in a patient with Turner's syndrome who had received estrogen-progestogen therapy for 13 years. At age 22 she was treated for primary amenorrhea and absence of secondary sexual characteristics. Urinary gonadotropin assay exceeded 32 mouse units/24 hours and infantile external genitalia, uterine hypoplasia, and impalpable ovaries were found. Cytogenetic studies confirmed a 45XO karyotype. For 13 years she received stilbestrol cyclically for 21 days with ethisterone, 5 mg twice daily, added for Days 16-21 of each cycle. Secondary sexual characteristics developed. After 13 years anemia developed, the uterus was found to be the size of a 20-week pregnancy, and an endometrial polyp protruding through the cervix showed squamous metaplasia. Following hysterectomy, histologic studies showed well-differentiated adenocarcinoma of the endometrium with some squamous metaplasia and osteoid formation. Metastases were not found. Similar cases treated with stilbestrol alone have been reported. Genetic predisposition is possible with this patient's X chromosome abnormality. However, estrogen therapy is thought to be a causative factor. Those receiving such therapy should have periodic gynecological examinations with curettage even when progestogens are also being used.

Topics: Adenocarcinoma; Adult; Diethylstilbestrol; Drug Therapy, Combination; Ethisterone; Female; Humans; Time Factors; Turner Syndrome; Uterine Neoplasms

Topics: Adenocarcinoma; Aged; Culture Techniques; Ethisterone; Female; Histocytochemistry; Humans; Intestinal Obstruction; Middle Aged; Ovarian Neoplasms; Progesterone; Steroids; Virilism